By Justin Kozak, Executive VP & Life Sciences Lead, Founder Shield The tide is turning in the once-booming biotech industry. Funding slowdowns and heightened competition are forcing companies to re-evaluate their strategies. Restructuring, including mergers and acquisitions (M&As) as well as workforce adjustments, has become a common
More
